From: The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients
Comparison | Overall survival | Disease-free survival | ||
---|---|---|---|---|
OR(95% CI) | p | OR(95% CI) | p | |
Early stage | ||||
DM vs. non DM | 1.67 (0.17–2.59) | 0.56 | 1.25 (0.33–4.73) | 0.73 |
DM (metformin) vs. DM (no metformin) | 1.54 (0.32–7.22) | 0.58 | 1.44 (0.09–2.14) | 0.31 |
DM (no metformin) vs. non DM | 0.62 (0.12–3.06) | 0.55 | 1.75 (0.34–8.79) | 0.49 |
DM (metformin) vs. non DM | 1.95 (0.23–4.10) | 0.96 | 1.78 (0.18–3.28) | 0.73 |
Late stage | ||||
DM vs. non DM | 1.25 (0.53–2.93) | 0.61 | 1.70 (0.29–1.67) | 0.42 |
DM (metformin) vs. DM (no metformin) | 4.28 (1.45–12.65) | 0.01* | 1.23 (0.07–0.68) | 0.01* |
DM (no metformin) vs. non DM | 1.56 (0.18–1.66) | 0.29 | 1.57 (0.52–4.71) | 0.41 |
DM (metformin) vs. non DM | 2.40 (0.91–6.35) | 0.07 | 1.36 (0.13–0.98) | 0.04* |